Cabaletta Bio, Inc. ((CABA)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
RESET-Myositis is a Phase 1/2 open-label study conducted by Cabaletta Bio, Inc. to assess the safety and efficacy of CABA-201, an investigational cell therapy, in patients with active idiopathic inflammatory myopathy or juvenile idiopathic inflammatory myopathy. The study aims to provide insights into treating these rare autoimmune diseases characterized by muscle inflammation and weakness.
The intervention being tested is CABA-201, a biological treatment given as a single intravenous infusion following preconditioning with fludarabine and cyclophosphamide. It targets B cells believed to contribute to the disease.
This interventional study follows a single-group assignment model with no masking, focusing on treatment as its primary purpose. Participants receive the same treatment, allowing researchers to evaluate its effects directly.
The study began on December 20, 2023, with its primary completion and estimated overall completion dates yet to be announced. The last update was submitted on July 15, 2025, indicating ongoing progress.
The study’s update could influence Cabaletta Bio’s stock performance positively if results show promise, potentially boosting investor confidence. It also positions the company competitively within the biotech industry, where advancements in autoimmune disease treatments are highly valued.
The study is currently recruiting, with further details available on the ClinicalTrials portal.